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The Hippo signaling network is a key regulator of cell fate. In the recent years, it was shown that its implication in cancer
goes well beyond the sole role of YAP transcriptional activity and its regulation by the canonical MST/LATS kinase
cascade. Here we show that the motin family member AMOTL1 is an important effector of Hippo signaling in breast
cancer. AMOTL1connectsHippo signaling to tumor cell aggressiveness.Weshow that both canonical andnoncanonical
Hippo signaling modulates AMOTL1 levels. The tumor suppressor Merlin triggers AMOTL1 proteasomal degradation
mediated by the NEDD family of ubiquitin ligases through direct interaction. In parallel, YAP stimulates AMOTL1
expression. The loss ofMerlin expression and the induction of Yap activity that are frequently observed in breast cancers
thus result in elevated AMOTL1 levels. AMOTL1 expression is sufficient to trigger tumor cell migration and stimulates
proliferation by activating c-Src. In a large cohort of human breast tumors, we show that AMOTL1 protein levels are
upregulated during cancer progression and that, importantly, the expression of AMOTL1 in lymph node metastasis
appears predictive of the risk of relapse. Henceweuncover an importantmechanismbywhichHippo signaling promotes
breast cancer progression by modulating the expression of AMOTL1.
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The Hippo signaling pathway controls organ size primarily through the
inhibition of cell proliferation and the stimulation of apoptosis. The
canonical Hippo pathway is composed of a cascade of kinases (MST1/2
and LATS1/2) leading to the phosphorylation and inhibition of twoFigure 1. AMOTL1 expression is higher in ER− breast tumors. (A
E-MTAB-365 and GSE21653 data sets (Mann-Whitney test). (B) AMOT
data sets (Mann-Whitney test). (C) AMOTL1 and ER transcript levels
(Bottom) The ER transcript levels are higher in the quartile with the htranscriptional cofactors, YAP and TAZ. In recent years, the implication
of this pathway in cancer development has been progressively
documented, focusing largely on the role of YAP and TAZ [38].
An impressive number of new components of the pathway were
progressively identified that connect Hippo signaling to various) AMOTL1 transcripts levels in ER− and ER+ breast tumors in
and AMOTL2 transcripts levels in relation to the ER status in both
are negatively correlated in both data sets (Spearman test, top).
ighest AMOTL1 expression (Mann-Whitney test).
Figure 2. AMOTL1proteinexpression isupregulatedduringbreast tumorprogression. (A)AMOTL1staining intensity ishigher in IDCcomparedwith toDCISo
the ER same status (Mann-Whitney test). (B) The proportions of normal breast tissue, DCIS, IDC, and lymph node tumorswith detectable AMOTL1 by IHC are
presented. AMOTL1 detection is more frequent with tumor progression. (C) Examples of AMOTL1 expression in breast normal epithelium (a, b, see also
SupplementaryFigureS1),DCIS(c,d), IDC(e,f),andinlymphnodemetastasis(g,h).Thestainingintensityappearshigherininvasivelesions.(D)Thequantificationo
AMOTL1 staining intensity in normal breast epithelium cells, DCIS, IDC, and lymph node tumor cells confirms that the expression is higher in invasive lesions
(Mann-Whitney test). (E) Staining of AMOTL1 shows that its expression is higher in IDC than in DCIS from the same biopsy. DCIS area; §IDC area. (F) The
quantificationof thestaining intensityofAMOTL1in IDCandDCISof thesamebiopsyconfirmshigherexpression intheinvasive lesions(Mann-Whitneytest). (G)A
Kaplan-Meyers analysis shows that the risk of relapse is significantly higher in patients with AMOTL1 positive staining of the lymph nodemetastasis.
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Figure 3. AMOTL1expression is negatively regulatedbyMerlin. (A) The expression levels ofAMOTL1andMerlin proteins in a set of 16breast cancer cell lines
displayaclearoppositepattern.(B)ThelevelsofMerlinandAMOTL1quantifiedbyWesternblotarenegativelycorrelated(Spearman'stest). (C)ThelevelofAMOTL1
increaseswhenMerlinproteinexpression is inhibited inBC52andMDA-MB-468usingshRNA(shMerlin#1and#2andcontrolshRNA,shctrl). (D)The inhibition
ofMerlinexpressioninBC52cells (shMerlin#1) leadstotheupregulationofAMOTL1mRNAlevelsmeasuredbyreal-timePCR(mean±SD)(Mann-Whitneytest).
(E)The transcriptionalactivityofYAP/TAZwasmeasured inBC52cellsexpressingshRNAcontrolorshRNAagainstMerlinusing theYAP/TAD-responsive reporter
8xGTIIC-lux (mean±SD)(Mann-Whitneytest). (F)Real-timePCRanalysisoftheAMOTL1transcript levelsuponsiRNA-mediatedYAPinhibitioninBC52cellswhere
NF2 isdownregulatedbyspecificshRNA(shMerlin#1and#2,controlshRNA:shctrl) (leftpanel) (Mann-Whitneytest). ImmunoblotanalysisofAMOTL1andYAP
protein level uponsiRNA-mediatedYAP inhibition inBC52cells stablyexpressingshRNAcontrol (shctrl) ofNF2 (shMerlin#1and#2) (rightpanel). (G)Correlation
between AMOTL1 transcript levels and YAP protein levels (measured by RPPA) in a set of 126 human breast tumors (Spearman test).
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density, or adhesion. Among them, the motin family of proteins
(AMOT, AMOTL1, and AMOTL2) was recognized as bona fide
component of the Hippo pathway [1].
AMOT was originally identified as a receptor for the antiangio-
genic factor angiostatin and a regulator of endothelial cell motility
[2,3]. Conservation of sequence, structure and interactors between
motins suggests redundancy in the family. Indeed, all three motins
were found to interact with actin and to regulate cellular polarity, cell
adhesion and [4,5]. But the mechanisms regulating these functions
are still largely unknown.
The motins contribute to Hippo signaling in different ways. They
bind to YAP and, depending on the experimental setting, either
inhibit or promote its activity [6,7]. They also bind to LATS kinases,
acting both as regulators and substrate [8]. Furthermore, AMOT was
shown to interact with the upstream Hippo regulator Merlin,
resulting in the modulation of the activity of the Rac1/MAPK
pathway [9]. Thus, the emerging picture is that the motins act as
molecular nodes allowing cross talk between major signaling pathways
involved in cell proliferation, migration, or polarity.
Few studies have addressed a possible involvement of motins in
cancer. AMOT was found to be highly expressed in blood vessels of
Kaposi’s sarcoma [2]. High mRNA levels of AMOT are associated
with a poor clinical outcome in breast cancer [10]. Recently, AMOT
expression was linked to venous invasion and poor prognosis and was
proposed to represent a potential prognostic marker in clear cell renal
carcinoma [11]. However, the regulation and the role of the motin
family members during cancer development and progression remain
largely unexplored.
In this report, we investigated the role of the motins in breast
cancer. We show that AMOTL1 expression is linked to breast cancer
aggressiveness and its expression in lymph node metastasis is
predictive of disease relapse. In mice, AMOTL1 expression in
tumor xenografts stimulates their growth. In vitro, we show that
AMOTL1 promotes the migration of tumor cells but also stimulates
tumor growth by activating c-Src. Finally, we demonstrate that
AMOTL1 activity is tightly regulated at different levels in breast
cancer cells. Indeed, YAP/TAZ stimulates AMOTL1 expression,
whereas NF2/Merlin induces the phosphorylation of the protein
leading to its degradation mediated by the NEDD family of ubiquitin
ligase. Thus, our results show that AMOTL1 expression is regulatedFigure 4. Merlin induces phosphorylation and degradation of AMO
reduced upon Merlin expression in BC52 tet on AMOTL1. (Left) AM
withMerlin vector (+) or control vector (−). (Right) Quantification of th
expression is inhibited by shRNA, overnight MG132 treatment of BC5
p27 was used as a positive control of MG132 activity (representative W
presented on the right graph (Kruskal-Wallis test). (C) AMOTL1 signal
(left). Numbers refer to the intensity score (0: no signal, 1: intermediat
intensity score upon expression of Merlin, a defective AMOTL1-bind
graph. AMOTL1 staining was scored in 150 transfected cells (right, K
ubiquitin ligase activity dead mutant of AIP4 (CS) or GFP-NEDD4 (n= 1
with Kruskal-Wallis test, immunofluorescence at the bottom). Scale ba
cells when the expression of AIP4 and NEDD4 is inhibited with siR
specificity of the anti-phospho-AMOTL1 S262 was tested on immu
phosphatase (top). (G) Merlin induces the phosphorylation of GFP-AM
was quantified by Western blot on immunoprecipitated GFP-AMO
Mann-Whitney test). (H) When tested using the same strategy as in
half-life of AmotL1S262A mutant (n = 4, Mann-Whitney test). For A,by both Yap-mediated canonical and NF2/Merlin driven noncanon-
ical Hippo signaling during breast cancer progression.
Materials and Methods
Human Sample Analysis
Analyses of human samples were performed in accordance with the
French Bioethics Law 2004-800 and the French National Institute of
Cancer Ethics Charter and after approval by the Institut Curie review
board and ethics committee that waived the need for written
informed consent from the participants. Women were informed of
the research use of their tissues and did not declare any opposition for
such research. Data were analyzed anonymously.
Breast Cancer Tissue Microarray (TMA)
Samples of primary breast tumors were surgically removed before
any radiation, hormonal, or chemotherapy treatment at Institut Curie
from 2005 to 2006. Our series of invasive breast tumors comprised all
TNBC and HER2 tumors available and equal number of consecutively
treated Luminal A and Luminal B tumors from the same period following
the same criteria. Based on clinicopathological examination, these tumors
were classified as invasive ductal carcinoma (IDC) and ductal carcinoma
in situ (DCIS). Inclusion of DCIS tumors in the TMA was performed
using the same criteria as for IDCs and were classified into the subtypes
TNBC, HER2, and Luminal A and B [31–34]. Breast molecular
subtypes were defined as follows: Luminal A + B according to [35]:
Luminal A: estrogen-receptor (ER) ≥ 10%, progesterone-receptor (PR) ≥
20%, Ki-67 b 14%; Luminal B: ER ≥ 10%, PR b 20%, Ki-67 ≥ 14%;
ER− PR−HER2+: ER b 10%, PR b 10%, HER2 2+ amplified or 3+;
ER− PR− HER2− (triple-negative breast cancers): ER b 10%, PR b
10%,HER2 0/1+ or 2+ nonamplified according to the American Society
of Clinical Oncology guidelines [36]. The second cohort of 126 invasive
breast tumors has been described elsewhere [37].
Gene Expression Analysis
Raw .cel files from two primary breast tumor gene expression data sets
were downloaded from NCBI GEO (GSE21653) and ArrayExpress
(E-MTAB-365) repositories and normalized with RMA algorithm before
selection of the optimal probeset for each gene using Jetset method [39].
The AMOTL1 signature was defined as follow: for both breast tumor
gene expression data set, we selected AMOTL1 correlated genes with aTL1 mediated by NEDD ubiquitin ligases. (A) AMOTL1 half-life is
OTL1 levels following doxycycline withdrawal when cotransfected
ree independent experiments (Mann-Whitney test). (B)WhenMerlin
2 does not modify AMOTL1 protein levels (sh Merlin#1 vs sh ctrl).
estern blot at left). The average of four independent experiments is
(in red) drops in BC52 tet on AMOTL1 cells expressing GFP-Merlin
e, and 2: strong). Scale bar is 50 μm. The quantification of AMOTL1
ing Merlin mutant (1-532), or GFP alone is presented on the right
ruskall Wallis test). (D) The same approach was used for AIP4, an
50 cells). GFP was used as a negative control (quantification on top
r is 50 μm. (E) The level of endogenous AMOTL1 increases in BC52
NA (right). [Left, quantification (n = 3) Kruskal-Wallis test]. (F) The
noprecipitated GFP-AMOTL1 treated (+) or not (−) with alkaline
OTL1 in 293 HEK cells. The level of phosphorylation of AMOTL1
TL1 and normalized from the amount of GFP-AMOTL1 (n = 4,
panel A, Merlin expression showed no significant impact on the
B, C, E, G, and H, values are provided as mean ± SEM.
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Bonferroni correction. Functional analysis was performed using the
Database for Annotation, Visualization, and Integrated Discovery. The
same strategywas used for the analysis of ovarian and colon cancer cohorts
presented in the supplementary data section.Cell Lines
MDA-MB-468, HEK293, Hela, and MCF10A cells were obtained
from the ATCC. BC52 cell line was developed at the Laboratory of
Preclinical Investigation in Curie Institute.Cells and Tumor Extracts
Cells and tumors were lysed in 50 mM Tris pH 7.4, 150 mM
NaCl, 1% NP-40, 4% SDS, 1 mM EDTA, protease (P8340), and
phosphatase (P5726) inhibitors (Sigma-Aldrich).
Antibodies
For Western blots. The following were used: Merlin (sc-332) and
NEDD4 (sc-25508) from Santa Cruz, CA; phospho-histone H3
ser10 (H0412), AMOTL1 (HPA001196), and actin (A2228) from
Sigma-Aldrich; YAP (#4912), p27 (#2552), AIP4 (#12117), and
cleaved caspase 3 (#9661) from Cell Signaling Technology (Ozyme,
16 AMOTL1 Promotes Breast Cancer Progression Couderc et al. Neoplasia Vol. 18, No. 1, 2016France); E-cadherin (610182) from BD Biosciences; phospho-Src
Y418 (44-660G) and phospho-FAK Y397 (44-624G) from Invitro-
gen; AMOTL1 p-S262 Covalab (pab0956-P, Lyon, France); and
Tead2 Covalab (pab0961-P, Lyon, France).
For immunofluorescence. The following were used: Merlin (sc-332,
Santa Cruz), AMOTL1 (HPA001196), and anti Flag M2 (F3165) from
Sigma-Aldrich. Images were acquired using a Leica DM 6000B
epifluorescence microscope and a 40× or a 63× oil immersion objective.
For aggregate cryosections. The following were used: AMOTL1
(HPA001196, Sigma Aldrich), phospho-histone H3 (H0412, Sigma-
Aldrich), and cleaved caspase 3 (#9661, Cell Signaling Technology).
For immunohistochemistry (IHC) on animal tissues. The following
were used: AMOTL1 (HPA001196, Sigma Aldrich) at 1/100, YAP
(sc-15407, Santa cruz) at 1/100, E-cadherin (#610182, BDBiosciences) at
1/100, and cleaved caspase 3 (#9661, Cell Signaling Technology) at 1/50.
siRNAs and shRNAs
Transfection of siRNA and shRNA was performed using lipofectamine
RNAimax solution (Invitrogen). The following were used: human AMOTL1
on-targetplus smartpool siRNA(#L-017595-01-0005)andnontargetingcontrol
siRNAs (D-001810-03), Dharmacon (Thermo Scientific, France); pLKO-
shRNA lentiviral constructs targeting human Merlin (TRCN0000018338,
called sh #1 and TRCN0000039974, called sh #2), AMOTL1
(TRCN0000130193),andnontargetingcontrolshRNA(SHC002V),Sigma,France.
Animal Studies
All mice studies were conducted following the guidelines of the
American Association of Laboratory Animal Care under an approved
protocol. Eight-week-old female nu/nu mice (Charles River, France)
were inoculated with 2 × 106 BC52 tet on AL1 cells in the neck
mammary fat pad. AMOTL1 expression was obtained by addition of
2 mg/ml of doxycycline to the drinking water supplemented with
10% sucrose. The tumors were measured twice per week.
IHC Analysis of Breast Cancer TMA
TMA consisted of replicate 1 mm–diameter tumor cores selected from
the most representative tumor areas (high tumor cell density) of each
tumor sample and a matched tissue core from adjacent nontumoral
(normal) breast epithelium. Three-micrometer paraffin sections were
deparaffinized before heat-induced epitope retrieval for 20 minutes in
EnVision FLEX Target Retrieval Solution (pH 6.1). Then, endogenous
activity was blockedwith a 3%hydrogen peroxide solution. Staining with
anti-AMOTL1 antibody (Covalab, Lyon, France), pab0883-P, 1:100,
was done using a Dako Autostainer plus stainer.Figure 5. AMOTL1 is associated with proliferation, migration, and EM
AMOTL1 signature in data set E-MTAB-365. (B) Summary of the corre
the same data set (Spearman test, E-MTAB-365) (see also Supplemen
with doxycycline show no EMT-like morphological changes (left). T
expression of the EMT markers (right). (D) EMT was induced by expo
right) leading to the downregulation of E-cadherin and increased AMO
treatment induces Yap nuclear translocation in MCF10A (left). Howev
and phosphorylation of Yap on S127 (right). (F) Three days of TGFβ a
Western blot shows that the treatment induces Tead2 expression (bo
whereas GFP-Tead2 promotes Yap nuclear accumulation (left). Scale
the right. More than 100 cells were counted for each condition. (H)
MCF10A induces the expression of AMOTL1.IHC of Mouse Tissues
Tissues were fixed using alcohol, formalin, and acetic acid and
embedded in paraffin. Four-micrometer–thick tissue sections were
prepared according to conventional procedures.
Cell Growth in Matrigel
Ninety-six–well cell culture plates were coated with 50 μl of 1:3
Matrigel (BDBiosciences) inDMEMoverlaid by a 1:1mix of 5 × 103 cells
andMatrigel. After 30minutes, this gel was overlaid by 100μl ofmedium.
Migration and Invasion Assay
A total of 5 × 105 cells were added to the top chamber with 8.0-μm
pore membranes (for migration evaluation) or Matrigel-coated
8.0-μm pore membranes (for invasion evaluation) (BD Biosciences,
France). After 16 hours, the cells that had migrated to the other side
of the insert were stained with phalloidin-rhodamine and counted.
AMOTL1 Half-Life Evaluation and Proteasome Inhibition
by MG132
BC52 tet on cells were transiently transfected with pRetroXAL1 or
PRetroXAL1S262A and either pBabe-Merlin or empty pBabe vector for 24
hours; then the cells were split into 6-well plates, anddoxycycline at 1μg/ml
was added in themedium. After 24 hours, the doxycycline was washed out,
cells were rinsed in PBS three times, and protein extraction was performed
at the indicated time points. AMOTL1half-life was determined as the time
needed to get 50% decrease of the initial amount of AMOTL1 (time = 0
hour). For the proteasome activity inhibition experiment, BC52 cells
expressing shRNA control or shRNA against AMOTL1 were treated
overnight by 5 μMMG132 before protein extraction.
Anti-AMOTL1 p-S262 Antibody
A 15-mer peptide corresponding to human AMOTL1 sequence and
containing phosphorylated S262 was coupled to keyhole lympet
hemocyanin. Rabbit immunization and purification against phosphor and
nonphospho peptides were done by Covalab (pab0956-P, Lyon, France).
Results
Expression of Motins in Human Breast Tumors
To evaluate the pattern of expression of the motins in breast tumors,
their transcript levels were analyzed in two independent published gene
expression data sets (E-MTAB-365 and GSE21653). No pattern of
expression specific to Luminal A, Luminal B,Her2-enriched, and basal-likeT in human breast tumors. (A) List of the GO terms associated to the
lations found between AMOTL1 and EMT markers’ expression for
tary Figure S3). (C) BC52 tet on AMOTL1 cells induced for 48 hours
he overexpression of AMOTL1 in BC52 cells does not induce the
sing MCF10A to 10 ng/ml of TGFβ for 24 hours (phase contrast at
TL1, N-cadherin, and Vimentin levels (left). (E) Three days of TGFβ
er, Western blot analysis of the cells shows no impact on the levels
t 10 ng/ml induces Tead2 nuclear accumulation in MCF10A (top).
ttom). (G) GFP expression does not affect Yap nuclear localization,
bar is 25 μm. The quantification of the experiment is presented on
The expression of constitutively nuclear Yap mutant (Yap 5SA) in
Neoplasia Vol. 18, No. 1, 2016 AMOTL1 Promotes Breast Cancer Progression Couderc et al. 17subtypes was observed (not shown).However, in both data sets, AMOTL1
expression was upregulated in tumors with ER-negative status (Figure 1A).
This was not the case for AMOTorAMOTL2 (Figure 1B), suggesting that
AMOTL1 expression might be more specifically associated to this moreinvasive tumor type. In addition, for both cohorts, AMOTL1 transcript
levels were found to be significantly higher in breast tumors expressing low
levels of ER transcripts. Finally, we also observed that AMOTL1 and ER
transcripts displayed an inverted correlation (Figure 1C).
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Invasive Tumors and Local Metastasis
Wenext evaluatedAMOTL1protein levels in a human breast cancer
TMA composed of 392 IDCs associated with noninvasive DCISs (n =
168), invaded lymph nodes (local metastasis, n = 122), and normal tissues
(n = 273) (see Supplementary Table S1 for a description of the tumors).
AMOTL1 staining intensity was not linked to the ER status. However, it
was stronger in IDC than in DCIS both in ER+ and ER− tumors,
suggesting that AMOTL1 expression might be linked to invasiveness
(Figure 2A). Overall, AMOTL1 was detected in about 13% of normal
tissues (compared with 80% of positive endothelial cells, Supplementary
Figure S1), 40% of DCISs, 58% of IDC tissues, and more than 87% of
lymph node metastases (Figure 2, B and C). In general, when detected,
AMOTL1 staining intensity was significantly higher in invasive lesions
(IDCand lymphnodemetastasis) than in benign ones (DCIS) or in normal
tissues (Figure 2D). Increase of AMOTL1 protein levels was also significant
between DCIS (mean intensity = 0.36) and IDC (mean intensity = 0.59)
from the same tumor (Figure 2, E and F). Finally, we observed that only
patients presenting a detectable AMOTL1 staining in the invaded lymph
nodes suffered of relapse during the follow-up period of 100 months as
opposed to none of the AMOTL1-negative group (Figure 2G). Despite an
important difference in the size of the groups, log-rank test showed that the
difference of clinical outcome was significant. Altogether, our results show
that AMOTL1 expression is linked to breast cancer progression and the risk
of relapse.
AMOTL1 Levels Are Regulated by Merlin and Yap in Breast
Cancer Cells
Little is known about the mechanisms that control motins protein
levels. AMOTL1, like the other motins, interacts with C-terminal domain
of the NF2/Merlin tumor suppressor [9] (Supplementary Figure S2A),
suggesting possible mutual regulation. Remarkably, when we evaluated
AMOTL1 and Merlin expression by Western blot in a set of 16 breast
cancer cell lines (see Supplementary Table S2 for a description), the two
proteins presented an obvious opposite expression profile (Figure 3, A and
B). WhenMerlin expression was inhibited with shRNA inMDA-MB-468
and BC52 cell lines, AMOTL1 levels increased (Figure 3C). In contrast, the
overexpression of AMOTL1 in the doxycycline inducible BC52 tet on
AMOTL1 cell line (Supplementary Figure S2B) or its downregulation by
siRNA (not shown) had no effect on Merlin levels. These results
demonstrate that AMOTL1 protein levels in breast tumor cells, and
possibly in breast cancer, are negatively regulated by Merlin.
We then measured AMOTL1 mRNA expression by real-time PCR
in BC52 cells upon inhibition of Merlin expression and found a near
two-fold increase (Figure 3D). Merlin is not a transcription factor but
inhibits the activity of the TEAD cotranscription factors YAP/TAZ.
WhenMerlin expression was abolished in BC52 cells, we observed more
than two-fold increase of YAP/TAZ transcriptional activity measured
with a synthetic YAP/TAZ-responsive luciferase reporter (Figure 3E).Figure 6. AMOTL1 induces cell migration and is negatively regulat
tet on AMOTL1 triggers migration in Transwell assay (the num
doxycycline on migration was tested on the parental BC52 tet o
depletion by siRNA reduces MDA-MB468 cell migration in Transw
from the lamellipodia in cells from a colony of BC52 tet on AMOT
see also Supplementary Figure S5B). Scale bar is 25 μm. The prese
GFP, GFP-Merlin, or GFP-Merlin 1-532 expression wasmeasured (r
The phospho-mimetic mutant of AMOTL1 (262D) does not localize
in contrast to wild-type (WT). The S262A mutant AMOTL1 is mor
μm. (E) Merlin expression does not delocalize AMOTL1 S262A fred b
ber
n c
ell a
L1
nce
igh
at t
e ob
omFurthermore, in MDA-MB468 cells depleted for Merlin, the extinction
of YAP expression by siRNA resulted in a decrease of AMOTL1 mRNA
and protein levels (Figure 3F). Finally, in a set of 126 invasive breast
tumors, distinct from the cohort used for IHC, we observed a significant
positive correlation between YAP protein levels and AMOTL1 mRNA
expression (P = .0022) (Figure 3G). Altogether, our results show that
AMOTL1 expression is regulated byHippo signalingmediated byMerlin
and Yap in breast cancer cells and possibly in tumors and that Merlin
likely acts upstream of Yap in this context.
Merlin Triggers AMOTL1 Degradation through
Direct Interaction
The interaction between the two proteins also suggests that Merlin
may regulate AMOTL1 stability directly. AMOTL1 expression was
transiently induced with a short pulse of doxycycline in BC52 cells
that express it under an inducible promoter. AMOTL1 decay was
then followed over time. When Merlin was coexpressed, the
quantification of four independent experiments showed that the
AMOTL1 half-life was 30% shorter (Figure 4A). Furthermore, when
Merlin expression was inhibited by shRNA, the level of AMOTL1
did not significantly increase if cells were already exposed to MG132,
suggesting that the proteasome was involved in Merlin downregu-
lation of AMOTL1 (Figure 4B). By immunofluorescence, we also
observed that the expression of GFP-Merlin was leading to a decrease
of overexpressed AMOTL1 signal in inducible BC52 tet on
AMOTL1, whereas a mutant of Merlin (1-532) unable to bind to
AMOTL1 as well as the GFP alone had no effect (Figure 4C).
Altogether, these results show that AMOTL1 degradation by the
proteasome requires direct interaction with Merlin. The ubiquitin
ligases NEDD4 and AIP4 were shown to regulate the stability of the
motins [12,13]. In BC52, we observed that AIP4 and NEDD4
expression resulted in a loss of AMOTL1 expression compared with
the control, and a mutant AIP4 devoid of ubiquitin ligase activity
(AIP4 CS) had no impact on AMOTL1 (Figure 4, D, upper and
lower panels). In contrast, the inhibition of AIP4 and NEDD4
expression using siRNA resulted in higher endogenous AMOTL1
levels (Figure 4E). AIP4 was shown to preferentially bind to motins
phosphorylated on a conserved serine in position 262 in human
AMOTL1 [12]. Using an antibody specific of AMOTL1 phosphor-
ylated on serine 262 (Figure 4F), we showed that Merlin induces an
increase of about 50% of S262 phosphorylation when cotransfected
with AMOTL1 in 293 T cells (Figure 4G). Finally, using the same
strategy as in Figure 4A, we also observed that Merlin expression did
not modify the half-life of the S262A mutant of AMOTL1 that
cannot be phosphorylated (Figure 4H). Altogether, our results show
that Merlin induces the phosphorylation of AMOTL1 on S262,
leading to its degradation, likely by increasing the binding of NEDD
family of ubiquitin ligases.yMerlin at the lamellipodia. (A) AMOTL1 induction (+DOX) in BC52
of independent experiments is indicated). The intrinsic effect of
ell line and was not significant (Mann-Whitney test). (B) AMOTL1
ssay (Mann-Whitney test). (C) AMOTL1 (green) is delocalized away
transfected with a plasmid expressing Merlin (red) (left images and
of AMOTL1 at the leading edge of BC52 tet on AMOTL1 cells upon
t graph) (Kruskal-Wallis test). Values are provided as mean ± SD. (D)
he leading edge of BC52 cells and shows a punctuated distribution,
viously associated to filamentous actin structures. Scale bar is 10
the leading edge of BC52 cells. Scale bar is 10 μm.</ce:figure
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Taking advantage of the two gene expression data sets previously
described (E-MTAB-365 and GSE21653), we defined an AMOTL1
transcriptional signature corresponding to the genes with the highest
positive correlation to AMOTL1 transcript levels (Supplementary Table
S3 and experimental procedures). With this signature, we performed an
unsupervised analysis and pathway enrichment study using all Gene
Ontology (GO) terms. The main GO terms associated with AMOTL1
signature (with P values smaller than 10−3 after Bonferroni correction)
corresponded to adhesion, angiogenesis, migration, and proliferation
(Figure 5A and Supplementary Table S4) for both E-MTAB-365 and
GSE21653 data sets. The angiogenesis signature was expected from
AMOTL1 role in angiogenesis and endothelial cell regulation [4,10].We
also confirmed the involvement of AMOTL1 in proliferation and
migration. An AMOTL1 signature was also produced from a set of colon
carcinoma (GSE64857) and ovarian tumor (GSE63885). They appeared
different from the breast cancer signature, suggesting a different role for
AMOTL1 depending on the tumor type, although some processes, such
as angiogenesis, were conserved (Supplementary Table S5). Strikingly, in
breast tumors, the list of genes whose expression strongly correlated with
AMOTL1 (P b 10-6) included EMT markers such as Vimentin, Twist,
Zeb1, Snail2, and α-smooth muscle actin (α-sma) in addition to a strong
negative correlation (P b 10−13) with E-cadherin (Figure 5B and
Supplementary Figures S3 and S4). EMT is recognized as an important
mechanism for carcinoma progression. AMOTL1 overexpression in
BC52however did not lead to noticeable changes in cellmorphology or in
EMT markers’ expression (Figure 5C). But when we stimulated
MCF10A with TGFβ, a classical model of EMT induction, we observed
a strong increase in AMOTL1 expression together with Vimentin and
N-cadherin and a reduction of E-cadherin levels (Figure 5D). In the light
of our results on the regulation of AMOTL1 expression, we tested if its
induction by TGFβ might require Yap and Merlin. TGFβ treatment of
MCF10A or BC52 had no impact on Merlin levels or phosphorylation
(not shown). However, we observed a marked nuclear accumulation of
Yap in the nuclei (Figure 5E). This was not linked to a change in Yap
expression or phosphorylation on S127 residue (Figure 5E), arguing for a
Hippo-independent mechanism. However, we observed an increase of
Tead2 expression by Western blot and its accumulation in the nuclei
(Figure 5F). We then tested if Tead2 could recruit Yap to the nucleus by
overexpressingGFP-Tead2 inMCF10A and evaluating the localization of
endogenous Yap. Indeed, GFP-Tead2 overexpression induced a very
obvious accumulation of Yap in the nuclei of MCF10A (Figure 5G).
Finally, when a constitutively active Yap5SAmutant was stably expressed
in MCF10A, it led to elevated levels of AMOTL1 protein (Figure 5H).
Together, our results suggest that, upon TGFβ stimulation, Tead2
accumulates and recruits Yap into the nucleus where together they
stimulate AMOTL1 expression. Thus, AMOTL1 expression is part of anFigure 7. AMOTL1 regulates proliferation of BC52 cells in vitro and in viv
days in BC52 leads to bigger aggregates inMatrigel (scale bar: 100μm). (B
quantified (bottom) is higher upon AMOTL1 induction (+DOX) (Mann-W
treated (DOX+) with doxycycline (IHC, upper pictures). Themean tumor
test). The insert shows representative tumors. (D) Quantification of ph
cryosections (left, Mann-Whitney test). Phospho-histone H3 expression
(Western blot, right). (E) AMOTL1, Src, phospho-Src (Y418), and phospho
(DOX+) comparedwithuntreated (DOX−) (Westernblot of a representati
by DMSO as a control or by Src inhibitor PP2 (100 nM) during 14 days. Sr
overexpress AMOTL1 (DOX+). (G) When expressed in BC52 cells, GFP-
lamellipodia. GFP is used as a negative control. Scale bar is 25 μm.EMTprogram in breast tumor cells and likely contributes to it. However,
its expression alone is not sufficient to trigger EMT.
AMOTL1 Expression Stimulates Migration of Breast Cancer Cells
Cells undergoing EMT acquire a more motile phenotype. Hence,
we investigated the role of AMOTL1 in breast cancer cell migration.
When AMOTL1 expression was induced in BC52 cells, it stimulated
migration measured by Transwell assay (Figure 6A). Cell invasion of a
Matrigel layer was also increased. However, when the effect of the
induction ofmigrationwas substracted, it appeared that AMOTL1had no
significant impact on invasion (Supplementary Figure S5A). Conversely,
whenAMOTL1 expressionwas inhibited using siRNA inMDA-MB-468
cells, migration was reduced two-folds compared with control (Figure 6B).
Taken together, our results confirm that AMOTL1 is a strong inducer of
breast cancer cell migration, in turn potentiating tumor invasion.
Merlin Antagonizes AMOTL1 Function during Cell Migration
When expressed in BC52 cells, AMOTL1 clearly localized to the
lamellipodia (Figure 6C). We also observed Merlin presence in this
structure. Very interestingly, upon GFP-Merlin expression,
AMOTL1 no longer remained at the leading edge (Figure 6, C,
left). A mutant of Merlin defective for AMOTL1 binding had no such
effect, indicating that the interaction with Merlin is necessary for
AMOTL1 delocalization (Figure 6, C, right). MG132 treatment did
not prevent AMOTL1 removal from lamellipodia, showing that local
degradation by Merlin is the cause (Supplementary Figure S5B). It
has been shown that phosphorylation of AMOT on the site
equivalent to S262 of AMOTL1 prevents the interaction with
F-actin. When expressed in BC52, the S262D phospho-mimicking
AMOTL1 mutant did not localize to the lamellipodia but presented a
vesicular distribution (Figure 6D). The S262A mutant was strongly
associated to actin filaments but could localize to the lamellipodia
although not as clearly as the WT AMOTL1 (Figure 6D).
Importantly, AMOTL1 262D was found to colocalize at the leading
edge of the BC52 cells with Merlin and was not efficiently displaced
(Figure 6E). Hence, based on our results, we propose that Merlin
induction of S262 phosphorylation releases AMOTL1 from actin,
leading to its removal from the lamellipodia.
AMOTL1 Promotes Proliferation of Breast Tumor Cells
through Src Activation
AMOTL1 impact on breast cancer cell proliferation was tested
in 3D Matrigel matrix. BC52 tet on AMOTL1 cells grew into bigger
aggregates in the presence of doxycycline (Figure 7A) and presented
an increased number of p-histone H3-positive cells (Figure 7B).
However, there was no modification of apoptosis as measured by
cleaved caspase 3 staining (Supplementary Figure S6, A and B).
When BC52 tet on AMOTL1 were injected in their fat pad, nude
mice that were fed with doxycycline in the drinking water grew biggero through Src activation. (A) AMOTL1 induction by doxycycline for 14
) Phospho-histoneH3 expressionmeasured on cryosections (top) and
hitney test). (C) AMOTL1 expression is induced in tumor from mice
size is bigger after 71 days in doxycycline-treatedmice (Mann-Whitney
ospho-histone H3 staining performed on DOX− and DOX+ tumor
is induced in mouse tumor upon induction of AMOTL1 expression
-FAK (Y397) show increased levels in doxycycline-treatedmouse tumor
ve tumor). (F) BC52 tet onAMOTL1aggregates inMatrigelwere treated
c inhibition predominantly inhibits the growth of BC52 aggregates that
AMOTL1 colocalizes with endogenous Src and appears to recruit it to
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3.4-fold (372 vs 1260 mm3) after 71 days (Figure 7C). Tumors
overexpressing AMOTL1 expressed higher levels of p-Histone H3
(Figure 7D) but no increase in apoptosis (Supplementary Figure
S6C). We next investigated which mitogenic signaling might be
activated by AMOTL1 overexpression in mouse tumors. Weobserved no difference in PAK phosphorylation (not shown) or
YAP nuclear localization (Supplementary Figure S6D), two pathways
regulated by the motins. Interestingly however, we found that the
levels of phosphorylated Src were higher in tumors overexpressing
AMOTL1 (Figure 7E). Consistently, the phosphorylation of a target
of Src, FAK, was upregulated (Figure 7E). Finally, BC52 tet on
22 AMOTL1 Promotes Breast Cancer Progression Couderc et al. Neoplasia Vol. 18, No. 1, 2016AMOTL1 cells were grown as aggregates in 3D and treated with the
Src inhibitor PP2. Whereas no obvious effect of PP2 was observed in
the absence of doxycycline, the growth of cell aggregates overex-
pressing AMOTL1 was severely inhibited (Figure 7F). Similarly to
what was described for AMOTL2, we observed that, in BC52 cells,
AMOTL1 colocalizes with endogenous Src and appears to recruit it to
lamellipodia (Figure 7G). Overall, our results show that AMOTL1
promotes proliferation of breast cancer cells in vitro and in vivo by
stimulating Src activity, possibly by localizing it to specific domains
where it can be activated.
Discussion
Evidences of motins’ involvement in cancer remain sparse. In breast
tumors, we observe that, in contrast to AMOT and AMOTL2,
AMOTL1 mRNA is differently expressed between the ER− and ER+
subgroups and that AMOTL1 and estrogen receptor mRNA are
negatively correlated. A link between AMOTL1 expression and the
ER status was previously reported [10], supporting the notion that
AMOTL1 plays a role in this group of tumors. Surprisingly, no
difference in staining intensity linked to the ER status was observed.
AMOTL1 protein expression however increases during tumor
progression, with the highest levels in lymph node metastasis. The
apparent discrepancy between AMOTL1 transcripts and protein
levels in relation to the ER status could be explained as follows:
AMOTL1 protein levels are higher in the more invasive IDC lesion,
irrespective of the ER status. However, the more aggressive ER−
tumors contain a higher proportion of invasive lesions. AMOTL1
transcripts levels are measured from biopsies that contain variable
proportions of DCIS and IDC, and their levels likely reflect the
enrichment in IDC lesions in ER− tumors.
Gene ontology analysis of human tumor data clearly link
AMOTL1 expression to EMT. AMOTL1 gene expression levels
correlate with several markers of EMT. Its protein expression
increases in response to EMT induced by TGFβ in MCF10A cells.
We did not observe morphological changes induced by siRNA-me-
diated downregulation of AMOTL1 in MCF10A (not shown). This
is consistent with a previous study [17] and in contrast with the
induction of EMT by AMOTL2 knock down in this cell type.
AMOTL2 and L1 were shown to bind and sequester Yap in the
cytoplasm. However, other studies also demonstrated a positive
regulation of Yap by the motins [6]. We observed that the
overexpression of AMOTL1 in BC52 cells and xenograft tumors
(Supplementary Figure S7) or MCF10A (not shown) had little impact
on endogenous Yap nuclear localization. Upon TGFβ stimulation, we
saw a clear accumulation of Yap in the nuclei of MCF10A that
AMOTL1 elevated levels could not prevent. Our results tend to
demonstrate that AMOTL1 expression is a consequence of the
activation of Yap in response to TGFβ and does not modulate Yap
significantly. The expression of AMOTL1 alone does not trigger
EMT in the tumor cells. Therefore, in breast tumors, our results show
that AMOTL1 likely participates in EMT, an important mechanism
for the transition from benign to invasive tumor. Cells from aggressive
tumors are more motile and tend to proliferate faster. Our GO
analysis again shows that AMOTL1 is associated to the regulation of
proliferation and migration. Indeed, we show that AMOTL1 is a
potent inducer of breast tumor cell growth in 3D cultures and in
xenograft tumor model. It does not display any growth inhibition
activity that was reported for motins in various cellular models [14,7].
The mechanisms appear distinct from those proposed for AMOT[9,15]. We did not observe an induction Rac and cdc42 activity by
AMOTL1, assessed by the pull down of the activated form of the
GTPases (not shown). Contrarily to AMOT [16], AMOTL1 had no
impact on p-ERK levels in cells in culture or in tumors (not shown).
As mentioned previously, AMOTL1 expression did not lead to the
changes in YAP regulation that were reported in previous studies
[6,7,17,18] such as YAP cytoplasmic sequestration or change in its
phosphorylation state (Supplementary Figure S7, A and B). Our
work shows that inducing Yap activity is unlikely to be the major
means by which AMOTL1 controls tumor growth. This observation
is corroborated by a previous study showing that AMOTL1
expression does not modify the mRNA level of CTGF and Cyr61,
bona fide targets of YAP [18]. We also identified genes that were
differentially expressed between two xenograft tumors where AMOTL1
expression was stimulated by doxycycline and two control tumors (no
doxycycline). The results are presented in Supplementary Table 6 and
show no Yap target genes in the list. In contrast, our results show that
AMOTL1 stimulates breast cancer cell proliferation by inducing Src
activity. Xenografts tumors overexpressing AMOTL1 show elevated
levels of active Src, and 3D cultures of BC52 cells become sensitive to PP2
Src inhibitor only when AMOTL1 is overexpressed. The mechanisms of
this regulation appear to involve the relocalization of Src in specific
compartment such as the lamillipodia, leading to its local activation
similarly to what was shown for AMOTL2 [19].
AMOTL1 promotes endothelial cell migration, and we observed
that it stimulates breast tumor cells’ migration too. Again, the absence
of activation of Rac and Cdc42 by AMOTL1 argues against their
involvement in the process. However, we cannot exclude that
AMOTL1 may regulate Rac activity locally similarly to the regulation
of RhoA activity by AMOT [20]. Indeed, AMOTL1 clearly localizes
in the lamellipodia, suggesting an active role in the dynamics of this
structure essential for migration. Merlin was previously shown to
inhibit migration in various models [21–23]. More recently, it was
shown that Merlin coordinates collective cell migration in response to
mechanical forces via the modulation of Rac activity. This function
apparently also involves angiomotin [24]. Our results suggest that
Merlin delocalization of AMOTL1 from the lamellipodia and
subsequent degradation could result in the localized inactivation of
Rac and participate in this process. An alternate possibility is that
degradation of AMOTL1 prevents local activation of Src, thus
impairing its role in cell migration. Delocalization and degradation of
AMOTL1 are a consequence of AMOTL1 S262 phosphorylation
induced by Merlin. Indeed, this event is sufficient to remove
AMOTL1 from the lamellipodia by preventing the interaction with
F-actin similarly to what was reported for AMOT [8]. In addition,
phosphorylation was shown to facilitate the binding of the NEDD
ubiquitin ligase [14] to AMOT and AMOTL1. But conflicting studies
reported either degradation [13] or stabilization of the proteins [12] as a
consequence. We show that, in BC52 cells, AIP4 and NEDD4 trigger
AMOTL1 degradation. S262 is a target for LATS1/2 kinases that bind to
motins. Interestingly, Merlin binds and activates LATS1/2 at the plasma
membrane [25]. It is thus possible that Merlin locally stimulates the
activity of LATS1/2 to phosphorylate AMOTL1.
Importantly, a remarkable study showed that Merlin expression
levels are downregulated during breast cancer progression and are
almost absent in metastasis, in a striking opposite pattern to the levels
of AMOTL1 that we observed in our cohort [26]. This observation,
together with our results, supports the idea that AMOTL1 acts as a
promoter of breast cancer progression, more specifically under
Neoplasia Vol. 18, No. 1, 2016 AMOTL1 Promotes Breast Cancer Progression Couderc et al. 23circumstances where the expression of Merlin is degraded. This
happens following Merlin phosphorylation, a consequence of AKT
activation, which is frequently observed in breast cancer. However,
we also showed that AMOTL1 expression is stimulated by Yap in
tumor cells and its mRNA levels correlate with Yap protein levels in
invasive breast tumors. In conclusion, our work demonstrates that
AMOTL1 is involved in breast cancer progression and that it is
regulated by Hippo members Yap and Merlin either independently or
synergistically. Besides breast cancer, our results show that AMOTL1
could participate in the aggressive phenotype of other cancers where
Merlin expression is occasionally lost such as glioma [27] melanoma
[28], mesothelioma [29], or renal cell carcinoma [30] or where
signaling leading to Yap or Taz activation expression is induced [30].
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